Fibrates in disorders of lipid metabolism;Fibrate bei lipidstoffwechselstörungen

Pharmazie in Unserer Zeit

Volumn 36, Issue 2, 2007, Pages 114-119

  Kostner, Karam M ^a   Kostner, Gerhard M ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ATROMID; BEZAFIBRATE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PLACEBO; ANTILIPEMIC AGENT; CLOFIBRIC ACID;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DRUG MECHANISM; EVIDENCE BASED PRACTICE; HEART INFARCTION; HUMAN; MONOTHERAPY; PROPHYLAXIS; RHABDOMYOLYSIS; ANIMAL; DIABETES MELLITUS; REVIEW;

ANIMALS; ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; CLOFIBRIC ACID; DIABETES COMPLICATIONS; HUMANS; LIPID METABOLISM DISORDERS;

EID: 34247868973     PISSN: 00483664     EISSN: 16151003     Source Type: Journal    
DOI: 10.1002/pauz.200600209     Document Type: Article

References (10)

1. Fruchart, J.C., Duriez, P.: Mode of action of Fibrates in the regulation of triglycerides and HDL-cholesterol metabolism. Drugs of Today 42 (2006), 39-64.
2. Vu-Dac, N., Schoonjans, K., Kosykh, V., Fruchart, J.C., Auwerx, J., Staels, B.: Fibrates increase human apolipoprotein Al expression through activation of th peroxisome proliferator-activated receptor. J. Clin. Invest. 96 (1995), 741-750.
3. Group of physicians of the Newcastle upon Tyne region: Trial of clofibrate in the treatment of ischaemic heart disease. Br. Med. J. 4 (1971), 767-775.
4. Frick, M.H., Elo, O., Haapa, K., et al.: The Helsinki heart study: primary prevention trial with gemfibrozil in iddle aged men with dyslipidemia: safety of treatment, changes in risk factors and incidence of CHD. N. Engl. J. Med. 317 (1987), 1237-1245.
5. Ericsson, C.G., Hamsten, A., Nilsson, J., Grip, L., deFaire, U.: Angiographic assessment of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347 (1996), 849-53.
6. Syvanne, M., Nieminen, M.S., Frick, H.: Association between lipoproteins and the progression of coronary and vein graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL-cholesterol. Circulation 98 (1998), 1993-1999.
7. Vakkilainen, J., Steiner, G., Ansquer, J.C., et al.: DAIS Group. Relationships between LDL particle size, plasma lipoproteins and progression of coronary artery disease. Circulation 107 (2003), 1733-1737.
8. The Bezafibrate Infarction Prevention Study: The Bip study Group. Secondary Prevention by raising HDL and reducing triglycerides in patients with coronary artery disease. Circulation 102 (2000), 21-27.
9. Rubins, H.B., Robins, S.J., Collins, D.: Gemfibrozil for the secondary prevention of CHD in men with low levels of HDL. N. Engl. J. Med. 341 (1999), 410-418.
10. Keech, A., Simes, R.J., Barter, P., et al.: Effects of long term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes (the FIELD study). Lancet 366 (2005), 1849-1861.